Comparative Pharmacology
Head-to-head clinical analysis: DURAPHYL versus THEO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURAPHYL versus THEO DUR.
DURAPHYL vs THEO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bronchodilator via beta-2 adrenergic receptor agonism; increases cAMP, relaxes bronchial smooth muscle.
Inhibits phosphodiesterase, increasing cAMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
5 mg orally twice daily, increased to 10 mg twice daily after one week if tolerated; maximum dose 20 mg twice daily.
300-600 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is 7–9 hours in adults with normal hepatic function; prolonged to 20–30 hours in hepatic cirrhosis or heart failure. In neonates, half-life may exceed 30 hours due to immature CYP450 enzymes.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Primarily hepatic metabolism (CYP1A2, CYP3A4) with renal excretion of metabolites. Less than 10% excreted unchanged in urine; approximately 70% recovered in urine as metabolites, 30% in feces.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Category C
Category C
Bronchodilator
Bronchodilator